TAVR Researchers Look To Lower-Risk Patients, Less Data Demands
This article was originally published in The Gray Sheet
Edwards Lifesciences' Sapien 3 valve looked good at the annual American College of Cardiology conference, including in intermediate-risk patients. Could it mean less follow-up demands for future approvals? Meanwhile, Medtronic continued to press its status as the only company with a TAVR device shown superior to surgery.
You may also be interested in...
The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.
Data from Medtronic’s CoreValve High Risk Study provide the firm with significant momentum toward expanding the FDA label for its transcatheter aortic valve replacement device. Based on the results, FDA says no advisory panel will need to meet for the firm’s high-risk surgery submission. Observers say the jury is still out on CoreValve versus Sapien question.
FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.